Navigation Links
Toward a more efficient therapy for a specific form of leukemia
Date:6/14/2011

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib.

Chronic myeloid leukemia (CML)

In our body, white blood cells combat foreign intruders, such as viruses and bacteria. In chronic myeloid leukemia, the formation of granulocytes, a particular type of white blood cells, is disturbed. The cells in the bone marrow which should grow into white blood cells show an uncontrolled increase in numbers as a result of a disruption in the maturing process. This uncontrolled growth may damage various tissues and adversely affect the production of normal blood cells in the bone marrow. A shortage of white blood cells makes patients more susceptible to infection.

The Philadelphia chromosome and imatinib

Under normal circumstances, our body very accurately regulates the production of white blood cells. This process is triggered by targeted activation of tyrosine kinase. In most forms of CML, a deviant chromosome is present - the Philadelphia chromosome - which gives rise to BCR-ABL1 fusion kinase. This kinase causes the trouble, leading to the increase in CML cells. Existing medicines (imatinib) therefore target this kinase.

While the effect of imatinib in CML patients is usually quite favorable, the use of imatinib is often not sufficient to remove the diseased cells from the body. Sometimes the disease is already too advanced at the start of treatment, or there is resistance.

Placental growth factor

Researchers from the team headed by Peter Carmeliet have studied the role of placental growth factor (PlGF) in leukemia and the therapeutic potential of PIGF inhibitors. Recent research conducted by Peter Carmeliet had already shown that antibodies against PlGF (antiPlGF) can inhibit the growth of particular tumors.

The present study proves that PlGF also plays a role in CML. The researchers have recorded increased PIGF values in both mice and humans. It appears that PIGF does not only stimulate the division of CML cells but also encourages the formation of blood vessels in bone marrow. Finally, inhibiting PlGF in mice with CML leads to higher life expectancy, even in those mice that are resistant to the current medicine imatinib. All of these findings indicate that the therapeutic potential of PIGF inhibitors in CML needs to be investigated further.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Attitudes toward end-of-life care: A survey of cancer patients and others in Korea
2. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
3. U.S. Pushes School Cafeterias Toward Healthier Offerings
4. Toward a vaccine for methamphetamine abuse
5. Negative attitudes toward fat bodies going global, study finds
6. Tiny gems take big step toward battling cancer
7. Top scientists unite to develop global scientific strategy Towards An HIV Cure
8. Toward a fast, simple test for detecting cholera rampaging in 40 countries
9. Major step taken toward an open and shared digital brain atlasing framework
10. Warning about benevolent sexism and mens apparently positive attitudes towards women
11. Early Steps Toward an Alzheimers Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... As ... Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: